We would like to note that although at the time that the roadmap guidelines were formulated tau PET was still considered an emerging technology, this imaging biomarker has evolved enormously in recent years and is now shaping up to be considered a primary biomarker for diagnosis of AD [81]. The gene discussed is MAPT; the disease is Alzheimer disease.